Blueprint
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): May 28,
2019
SANARA MEDTECH INC.
Formerly named
WOUND MANAGEMENT TECHNOLOGIES, INC.
(Exact name of registrant as specified in its
charter)
Texas
|
000-11808
|
59-2219994
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
1200
Summit Avenue, Suite 414 Fort
Worth, Texas
|
76102
|
(Address
of principal executive offices)
|
(zip
code)
|
Registrant’s telephone number, including area code:
(817)-529-2300
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
checkmark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On May
28, 2018, the Board of Directors (the “Board”) of
Sanara MedTech Inc. (the Company) voted to (i) expand the size of
the Board from three (3) to four (4) persons effective immediately
(ii), elect J. Michael (Mike) Carmena as a Board member with the
office of Vice Chairman and (iii) appoint Zachary (Zach) B. Fleming
and Shawn M Bowman as new Company Officers. Additionally, the
Company eliminated the role of Chief Executive Officer and
appointed Mr. Carmena as the Principal Executive
Officer.
As part
of the new strategic plan initiated by the Board, the Company will
manage its operations in two separate divisions going forward: (1)
the Surgical Division and (2) the Wound Care Division.
Zachary
B. Fleming has been appointed to the position of President,
Surgical Division. Mr. Fleming joined the Company as Vice President
of Sales in November 2017 and was promoted to Vice President,
Surgical in September 2018. Mr. Fleming successfully led the
surgical sales organization to growth of approximately
forty-percent in 2018 and will be responsible for the continued
expansion and management of the surgical sales force as well as new
product introductions. Mr. Fleming has spent over thirteen years in
the medical industry with Healthpoint Biotherapeutics, Smith &
Nephew and Sanara MedTech. Mr. Fleming earned a Bachelor of Science
from Indiana University.
Shawn
M. Bowman has been appointed to the position of President, Wound
Care Division and will lead the strategic expansion of the six
previously discussed focus areas of wound care. Mr. Bowman
previously served as the Company’s Vice President and General
Manager, Wound Care since September 2018. Mr. Bowman is a
well-respected leader in chronic wound care with eighteen years of
key experience in the medical device, biologics and pharmaceutical
industries. Prior to joining Sanara MedTech, Mr. Bowman built two
successful teams as Senior Vice President of Wellsense, and as a
National Sales Director for Smith & Nephew’s Advanced
Wound Management Division. Mr. Bowman earned a Bachelor of Science
in Marketing from the University of Connecticut and is pursuing his
EMBA at Kellogg School of Management.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
WOUND
MANAGEMENT TECHNOLOGIES, INC. |
|
Date:
May 31, 2019
|
|
|
|
|
By:
|
/s/
Michael
D. McNeil
|
|
|
|
Name:
Michael D. McNeil
|
|
|
|
Title:Chief
Financial Officer
|
|